Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Vicente Alfaro"'
Autor:
Ramón Salazar, Carmen Cuadra, Marta Gil-Martín, Andrea Vandermeeren, Vicente Alfaro, Cinthya Coronado
Publikováno v:
Case Reports in Oncology, Vol 5, Iss 2, Pp 354-358 (2012)
Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-
Externí odkaz:
https://doaj.org/article/71605b02e0cb4ca7ad1d2791bdfae35d
Autor:
Carmen Kahatt, Cinthya Coronado, Pilar Lardelli, Claudia Silvia Corrado, Elena Roy, Vicente Alfaro, Bernardo Miguel-Lillo, Sonia Extremera, Arturo Soto-Matos, Sergio Szyldergemajn
Publikováno v:
Marine Drugs, Vol 9, Iss 6, Pp 1007-1023 (2011)
Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that o
Externí odkaz:
https://doaj.org/article/71d4efc9e46b416b8d484543c69d0239
Publikováno v:
Universidad Nacional Mayor de San MarcosRepositorio de Tesis - UNMSM.
En este trabajo se evaluaron dos grupos de pacientes con diagnóstico de ingreso de “síndrome coronario agudo”, con la intención de medir el nivel de conocimiento acerca de su medicación (acción del medicamento, modo, frecuencia de administra
Externí odkaz:
http://cybertesis.unmsm.edu.pe/handle/cybertesis/2333
Autor:
Jesús Molina, Amelia González-Gamarra, Leovigildo Ginel, Mª Encarnación Peláez, Juan Luis Juez, Antonio Artuñedo, Gonzalo Aldana, Enriqueta Quesada, Joan Josep Cabré, Antonio Gómez, Manuel Linares, Maria Teresa Marín, Pilar Yolanda Sanchez, Leonor Núñez, Jaime Gonzálvez, Enrique Mascarós, Javier López, Agustina Cano, José Herrero, María Carmen Serra, Enrique Cimas, Marta Pedrol, Juan Vicente Alfaro, Federico Martinón-Torres, Isabel Cifuentes, Cristina Méndez, Daniel Ocaña, on behalf of the CAPPRIC study group
Publikováno v:
Microorganisms, Vol 9, Iss 3, p 508 (2021)
The real burden of community-acquired pneumonia (CAP) in non-hospitalized patients is largely unknown. This is a 3-year prospective, observational study of ambulatory CAP in adults, conducted in 24 Spanish primary care centers between 2016–2019. So
Externí odkaz:
https://doaj.org/article/8a174717889e4af9a6bda0ecc915b118
Autor:
Ignace Vergote, Laura Vidal, Giovanni Scambia, Vicente Alfaro, Isabelle Ray-Coquard, Stephanie Gaillard, Cristian Fernandez, Carmen Kahatt, Ana Oaknin, Ivor Benjamin, Beatriz Pardo-Burdalo, Rebecca Kristeleit, Nicoletta Colombo, Domenica Lorusso, Patricia Pautier, Miguel Aracil, David M. O'Malley, Zsuzsanna Papai, Antonio Nieto, Ali Zeaiter
Publikováno v:
Gynecologic Oncology. 163:237-245
Objective The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer. Methods Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a605c9316e82ecae6b5fbe693738ce0c
https://doi.org/10.1016/j.ygyno.2021.08.032
https://doi.org/10.1016/j.ygyno.2021.08.032
Autor:
J.A. Lopez-Vilariño, Eva Guerra, Victor Moreno, Emiliano Calvo, Vicente Alfaro, R Kristeleit, Mariano Siguero, Neus Basté, Martin Forster, Valentina Boni, Ali Zeaiter, Ignacio A. Romero, Carmen Kahatt
Publikováno v:
International Journal of Gynecological Cancer
ObjectiveSecond-line treatment of endometrial cancer is an unmet medical need. We conducted a phase I study evaluating lurbinectedin and doxorubicin intravenously every 3 weeks in patients with solid tumors. The aim of this study was to characterise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a449a1f6daee56e6001e751d6fd2651b
https://doi.org/10.1136/ijgc-2021-002881
https://doi.org/10.1136/ijgc-2021-002881
Autor:
Federico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, Sant P. Chawla, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Ali Zeaiter, Victor Moreno, Enrique Sanz-García, Ahmad Awada, Ana Santaballa, Vivek Subbiah
Publikováno v:
Scientia
European journal of cancer (Oxford, England : 1990)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
European journal of cancer (Oxford, England : 1990)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Lurbinectedin; Neuroendocrine tumours; Small cell Lurbinectedina; Tumores neuroendocrinos; Célula pequeña Lurbinectedina; Tumors neuroendocrins; Cèl·lula petita Background Patients with neuroendocrine tumours (NETs) need alternative therapies aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a1d605cd1021c2a275ca1c4d159c945
https://hdl.handle.net/11351/8198
https://hdl.handle.net/11351/8198
Autor:
Jose María Mazarico, Vicente Alfaro, Luis Paz-Ares, Elizabeth Jimenez-Aguilar, Javier Baena, Ali Zeaiter, Carmen Kahatt, Andrea Modrego
Publikováno v:
Future Oncology. 17:2279-2289
Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer. The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad8907877698650856fe422556a3a4d
https://doi.org/10.2217/fon-2020-1212
https://doi.org/10.2217/fon-2020-1212
Autor:
Antonio Antón, Vivek Subbiah, Ahmad Awada, Jacob Sands, Maria Eugenia Olmedo, Maite Martínez, Cristian Fernandez, Sant P. Chawla, Rafael López, María Ángeles Sala, Benjamin Besse, Ali Zeaiter, Khalil Zaman, Victor M. Villalobos, Victor Moreno, Armando Santoro, Jennifer Arrondeau, María Jesús Rubio, Jose Manuel Trigo, Manolo D'Arcangelo, Carmen Kahatt, Joaquín Mosquera-Martinez, Vicente Alfaro, J. Gomez, Jean Pierre Delord, Javier Valdivia, Santiago Ponce, Valentina Boni, Solange Peters, John Sarantopoulos, Rebecca Kristeleit, Luis Paz-Ares, Luciano Wannesson
Publikováno v:
The Lancet Oncology. 21:645-654
Summary Background Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4669b6e21ccf393ea443de6fddaa8cc
https://doi.org/10.1016/s1470-2045(20)30068-1
https://doi.org/10.1016/s1470-2045(20)30068-1
Autor:
Enrique M. Ocio, Angelo Michele Carella, Maria-Victoria Mateos, Argiris Symeonidis, Heather Oakervee, Raymond H. Banh, Chang-Ki Min, Roman Hájek, Richard Greil, Pieter Sonneveld, Shang-Yi Huang, Carmen Kahatt, Ivan Spicka, Nathalie Meuleman, Sonia Extremera, James D'Rozario, Paul Cannell, Sara Martinez, Meletios A. Dimopoulos, Heinz Ludwig, Vicente Alfaro
Publikováno v:
Annals of Hematology
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca21caae1db2c673a339baafea4841c
https://doi.org/10.1007/s00277-019-03739-2
https://doi.org/10.1007/s00277-019-03739-2